Why the extended-spectrum β-lactamases SHV-2 and SHV-5 are "hypersusceptible" to mechanism-based inhibitors

Biochemistry

Volumn 48, Issue 41, 2009, Pages 9912-9920

  Kalp, Matthew ^a   Bethel, Christopher R ^c   Bonomo, Robert A ^b,c   Carey, Paul R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITE; BINDING POCKETS; CEFOTAXIME; CEFTAZIDIME; CLAVULANIC ACID; COMPARATIVE ANALYSIS; CRYSTALLOGRAPHIC DATA; ENAMINE INTERMEDIATES; ENAMINES; LACTAMASES; RAMAN BAND SHAPE ANALYSIS; RAMAN SPECTROSCOPIC; SITE-SPECIFIC; STOPPED-FLOW KINETICS; TAZOBACTAM; TEM; WILD TYPES;

AMPHIPHILES; BINDING SITES; CARBOXYLIC ACIDS; RAMAN SPECTROSCOPY; SPECTROSCOPIC ANALYSIS;

SINGLE CRYSTALS;

AMPICILLIN; BETA LACTAMASE SHV; CEFOTAXIME; CEFTAZIDIME; CLAVULANIC ACID; ENAMINE; IMINE; NITROCEFIN; SULBACTAM; TAZOBACTAM;

ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; KINETICS; NONHUMAN; POPULATION; PREDICTION; PRIORITY JOURNAL; RAMAN SPECTROMETRY; WILD TYPE;

BETA-LACTAMASES; CATALYTIC DOMAIN; CEPHALOSPORINS; CRYSTALLOGRAPHY, X-RAY; KINETICS; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, SITE-DIRECTED; PLASMIDS; SERINE; SPECTRUM ANALYSIS, RAMAN; SULBACTAM;

EID: 70350042195     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi9012098     Document Type: Article

References (27)

1. Paterson, D. L., and Bonomo, R. A. (2005) Extended-spectrum β-lactamases: A clinical update. Clin. Microbiol. Rev. 18, 657-686.
2. Paterson, D. L., Ko, W. C., Von Gottberg, A., Mohapatra, S., Casellas, J. M., Goossens, H., Mulazimoglu, L., Trenholme, G., Klugman, K. P., Bonomo, R. A., Rice, L. B., Wagener, M. M., McCormack, J. G., and Yu, V. L. (2004) International prospective study of Klebsiella pneumoniae bacteremia: Implications of extended-spectrum β-lactamase production in nosocomial infections. Ann. Intern. Med. 140, 26-32.
3. Paterson, D. L., Ko, W. C., Von Gottberg, A., Mohapatra, S., Casellas, J. M., Goossens, H., Mulazimoglu, L., Trenholme, G., Klugman, K. P., Bonomo, R. A., Rice, L. B., Wagener, M. M., McCormack, J. G., and Yu, V. L. (2004) Antibiotic therapy for Klebsiella pneumoniae bacteremia: Implications of production of extended-spectrum β-lactamases. Clin. Infect. Dis. 39, 31-37.
4. Rodriguez-Bano, J., and Pascual, A. (2008) Clinical significance of extended-spectrum β-lactamases. Expert Rev. Anti-Infect. Ther. 6, 671-683.
5. Kliebe, C., Nies, B. A., Meyer, J. F., Tolxdorff-Neutzling, R. M., and Wiedemann, B. (1985) Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob. Agents Chemother. 28, 302-307.
6. Knothe, H., Shah, P., Krcmery, V., Antal, M., and Mitsuhashi, S. (1983) Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11, 315-317. (Pubitemid 14213754)
7. Jacoby, G. A. (1997) Extended-spectrum β-lactamases and other enzymes providing resistance to oxyimino-β-lactams. Infect. Dis. Clin. North Am. 11, 875-887.
8. Jacoby, G. A., and Medeiros, A. A. (1991) More extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 35, 1697-1704.
9. Philippon, A., Labia, R., and Jacoby, G. (1989) Extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 33, 1131-1136.
10. Livermore, D. M., Canton, R., Gniadkowski, M., Nordmann, P., Rossolini, G. M., Arlet, G., Ayala, J., Coque, T. M., Kern-Zdanowicz, I., Luzzaro, F., Poirel, L., and Woodford, N. (2007) CTX-M: Changing the face of ESBLs in Europe. J. Antimicrob. Chemother. 59, 165-174.
11. Livermore, D. M., and Hawkey, P. M. (2005) CTX-M: Changing the face of ESBLs in the UK. J. Antimicrob. Chemother. 56, 451-454.
12. Knox, J. R. (1995) Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: Mutations, specificity, and three-dimensional structure. Antimicrob. Agents Chemother. 39, 2593-2601.
13. Huletsky, A., Knox, J. R., and Levesque, R. C. (1993) Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type β-lactamases probed by site-directed mutagenesis and three-dimensional modeling. J. Biol. Chem. 268, 3690-3697.
14. Nukaga, M., Mayama, K., Hujer, A. M., Bonomo, R. A., and Knox, J. R. (2003) Ultrahigh resolution structure of a class A β-lactamase: On the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J. Mol. Biol. 328, 289-301.
15. Orencia, M. C., Yoon, J. S., Ness, J. E., Stemmer, W. P., and Stevens, R. C. (2001) Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. Nat. Struct. Biol. 8, 238-242.
16. Helfand, M. S., and Bonomo, R. A. (2005) Current challenges in antimicrobial chemotherapy: The impact of extended-spectrum β-lactamases and metallo-β-lactamases on the treatment of resistant Gram-negative pathogens. Curr. Opin. Pharmacol. 5, 452-458.
17. Helfand, M. S., Totir, M. A., Carey, M. P., Hujer, A. M., Bonomo, R. A., and Carey, P. R. (2003) Following the reactions of mechanism-based inhibitors with β-lactamase by Raman crystallography. Biochemistry 42, 13386-13392.
18. Padayatti, P. S., Helfand, M. S., Totir, M. A., Carey, M. P., Carey, P. R., Bonomo, R. A., and van den Akker, F. (2005) High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 β-lactamase. J. Biol. Chem. 280, 34900-34907.
19. Padayatti, P. S., Helfand, M. S., Totir, M. A., Carey, M. P., Hujer, A. M., Carey, P. R., Bonomo, R. A., and van den Akker, F. (2004) Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 β-lactamase: 1.63 Å crystal structure. Biochemistry 43, 843-848.
20. Totir, M. A., Padayatti, P. S., Helfand, M. S., Carey, M. P., Bonomo, R. A., Carey, P. R., and van den Akker, F. (2006) Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine β-lactamase intermediates. Biochemistry 45, 11895-11904.
21. Hujer, A. M., Hujer, K. M., and Bonomo, R. A. (2001) Mutagenesis of amino acid residues in the SHV-1 β-lactamase: The premier role of Gly238Ser in penicillin and cephalosporin resistance. Biochim. Biophys. Acta 1547, 37-50.
22. Carey, P. R. (2006) Spectroscopic characterization of distortion in enzyme complexes. Chem. Rev. 106, 3043-3054.
23. Kalp, M., Totir, M. A., Buynak, J. D., and Carey, P. R. (2009) Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 β-lactamases: Raman crystallographic evidence. J. Am. Chem. Soc. 131, 2338-2347.
24. Sulton, D., Pagan-Rodriguez, D., Zhou, X., Liu, Y., Hujer, A. M., Bethel, C. R., Helfand, M. S., Thomson, J. M., Anderson, V. E., Buynak, J. D., Ng, L. M., and Bonomo, R. A. (2005) Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 β-lactamase. Insights into the mechanism of inhibition. J. Biol. Chem. 280, 35528-35536.
25. Bush, K., Macalintal, C., Rasmussen, B. A., Lee, V. J., and Yang, Y. (1993) Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob. Agents Chemother. 37, 851-858.
26. Cartwright, S. J., and Coulson, A. F. (1979) A semi-synthetic penicillinase inactivator. Nature 278, 360-361.
27. Rizwi, I., Tan, A. K., Fink, A. L., and Virden, R. (1989) Clavulanate inactivation of Staphylococcus aureus β-lactamase. Biochem. J. 258, 205-209. (Pubitemid 19062271)